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Abstract - Tissue engineering is a multidisciplinary field that combines aspects of biology, material sciences, 
engineering and medicine - the ultimate goal being able to fabricate replacement tissues and/or organs for an 
ageing population. However, parallel to this milestone, is the exploitation of the biomimetic constructs as 
feasible alternatives to in vivo/ex vivo toxicity testing models due to their accurate representation of innate 
tissue and organs. Herein, we summarise a range of concepts within tissue engineering with a particular 
emphasis on biological material selection and implications to animal testing.  
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
_______________________________________________________________________________________ 
 
INTRODUCTION 
 
Tissue engineering and scaffolds 
Tissue engineering, a term proposed at a National 
Science Foundation workshop in 1988, described 
the subject area as “an interdisciplinary field that 
applies the principles of engineering and life 
sciences towards the development of biological 
substitutes that restore, maintain or improve tissue 
function”[1]. In light of this, many consider the 
repair or replacement of diseased and damaged 
tissues/organs - being able to create autologous 
engineered transplant material and/or procure 
direct tissue replacements on demand - as the “gold 
standard” of tissue engineering. Yet, an important 
parallel aspect of the applied technology is the 
ability to develop accurate representation of tissues 
and organs that can be used for drug development 
and toxicology studies[2]. Accordingly, the field 
has now been defined as “the application of 
biological, chemical, and engineering principles 
towards the repair, restoration, or regeneration of 
living tissues using biomaterials, cells and factors 
alone or, in combination”[3] which accurately 
summarises the close interaction between these 
distinct academic subjects, as well as the multi-
faceted relationship between the physical and 
biological fundamentals (Figure 1). 
One of the key defining parameters for tissue 
engineering is the ability to control or direct the 
growth, differentiation, and behaviour of a specific 
cell population by modulating its culture substrate 
- a crucial factor that needs to be considered 
especially for stem cells due to their pluripotent 
nature. These scaffolds (also known as matrices, 
biological constructs, framework) are considered 
to be the most important element within tissue 
engineering strategies because they not only 
provide the mechano-architectural framework, at 
the micro- and macro-scale, required to generate 
the biological “mass” of a tissue or rudimentary 
organ, but they also allow the appropriate cell 
signalling and biological pathways, via extra-
cellular matrix (ECM) and cell-to-cell interactions, 
to occur during culture and growth. In addition, 
they must also provide an appropriate environment 
whereby the cells are able to maintain the correct 
phenotype and synthesise or express the required 
proteins, growth factors, and molecules for that 
specific tissue function[4].  
Tissue engineering is an interdisciplinary field 
that applies the principles of engineering and the 
life sciences towards the development of biological 
substitutes that restore, maintain, or improve tissue 
function[1]. These biologically suitable substitutes 
for organs and tissues can be used for 
pharmaceutical, diagnostic, or research purposes.  
However, the eventual goal is to create autologous, 
engineered transplant material that can be used to 
replace tissues that have been damaged by disease 
or injury[2]. 
 
MATERIALS AS SCAFFOLDS 
 
The selection of the most appropriate material for  
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tissue engineering applications is frequently seen 
as the most challenging aspect of the field due to 
the intimate relationship between a cell and its 
culture substrate. Several parameters have been 
identified as being crucial for selecting a suitable 
scaffold including:  
 
1. Biocompatibility: the material must not 
impact negatively on the cells that are to 
be cultured on it, i.e. it will allow the 
attachment, spreading, proliferation, 
differentiation, and/or migration of the 
cells (within the correct phenotype).  
2. Appropriate characteristics: the material 
must possess the correct mechanical and 
physical characteristics in its native and 
three-dimensional (3D) form. It should 
also be easy to generate, manufacture, and 
manipulate. The cost of the material, either 
as a direct cost or indirect cost - via 
addition modification - is also often 
considered. 
3. Toxicity: the material, including any 
breakdown products, must neither be 
harmful nor elicit an immune response. 
4. Ethics: the material should ideally be 
derived from an ethically-derived source 
where appropriate, e.g. non-animal based, 
“green technology”, non-human organ 
harvested. 
As such, the scaffold-based materials used for 
tissue engineering applications[5] and associated 
cell-based screening models, are often identified as 
synthetic or (natural) biological materials. 
Synthetic materials have been obvious candidates 
for these applications due to their relative ease of 
procurement, as well as the natural ability for 
manipulation and control of their chemical and 
physical characteristics to suit a specific 
application. In contrast, biological materials - 
being naturally compatible - allow the appropriate 
cell-to-interface responses to occur which 
ultimately result in the correct cell or biological 
characteristics and behaviour to be expressed[6]. A 
large number of natural scaffolds currently in use 
employ biopolymers that can be found in existing 
ECMs. Examples include protein-based materials 
(e.g. fibrin, collagen, and gelatin) and 
polysaccharide-based materials (e.g. alginate, 
chitosan, glycosaminoglycans, hyaluronic acid, 
and methacrylate)[7-10]. Thus far, several cancer 
models that utilise synthetic scaffolds have been 
created[11], however only a small number of 3D 
models use natural materials[12, 13]. Curiously, a 
multitude of biopolymers have thermoresponsive 
solubility behaviour, opening up opportunities to 
establish systems that dissolve or gel at body 
temperature[14]. A summary of the range of current 
materials used for tissue engineering is shown in 
Table 1. 
 
 Figure 1. Schematic summarising the relationship and overlap between distinct subject areas within tissue engineering 
(TE).
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2D vs 3D scaffolds 
The advancement of novel biomaterials for in vitro 
cell culture in three-dimensional (3D) 
environments has become more prevalent in recent 
years[16-21]. The catalyst for this advancement is to 
overcome the limitations of current two-
dimensional (2D) cell culture practices. 2D cell 
culture is ubiquitously employed to study a vast 
array of biological processes, despite clear 
structural and mechanical differences compared to 
the in vivo environment. In vivo, cells are situated 
within a complex extracellular matrix (ECM). The 
physical and biochemical properties of the ECM 
have a significant impact on a multitude of critical 
physiological and pathological processes[22]. 
In order to suitably recreate the in vivo 
environment in a controlled in vitro setting, the 
mechanical and chemical inputs have to be 
carefully modified, as they affect the ability of the 
cells to grow, proliferate, differentiate, and mature. 
Scaffolds help mimic the physical in vivo 
environment, allowing the cells to grow with 
appropriate morphologies. The scaffolds enable 
cell attachment and migration, retention, and 
presentation of biochemical factors. As well as 
providing mechanical support, and allowing the 
diffusion of nutrients, oxygen, and waste[2]. 
Significant differences of the biology and 
morphology between cells grown on 2D and 3D 
environments has been observed[23, 24]. For 
example, cancer cells cultured in vitro lose many 
of their in vivo features, due to a lack of 
environmental signals[16], caused by the 
deprivation of the tissue matrix that regulates 
tumour progression. This results in cell phenotype 
and gene expression changes. Ultimately, 
important aspects of tumour biology (most 
importantly angiogenesis and metastasis) cannot 
be properly assessed in monolayer culture[25-28]. 
In contrast, cancer cells cultured in a 3D 
scaffold exhibit decreased proliferation rates and 
an increased chemotherapy resistance, compared 
to cells grown in 2D monolayers, appearing to 
revert back to the original tumour phenotype[29]. 
 
The need for accurate drug screening models 
Within the drug discovery process, traditional in 
vitro-based studies rely on the culture of cells as a 
monolayer on standard tissue culture plastic; often 
referred to as two-dimensional (2D) cell culture. 
However, this pseudo microenvironment does not 
accurately mimic the native conditions 
experienced by a cell in vivo, i.e. a 3D growth 
environment. Accordingly, using an inadequate 
and flawed experimental setup can lead to 
erroneous decisions during drug development - 
resulting in (expensive) false-positive therapeutic 
drugs being identified, progressed, and/or 
approved during the toxicity screening process. It 
has been reported that 3.5% of drugs, approved 
from 1980-2009 in the US, were withdrawn from 
the market due to safety concerns[30]. As such, the 
ability to accurately mimic the real environment 
experienced by specific organs, tumours, or 
localised tissue would be considered invaluable 
during the early stages within the drug discovery 
pipeline.  
 
Drug testing: 2D versus 3D cell culture  
Prior to any in vivo studies being performed, 
preliminary work is often carried out using 
simplified in vitro tests - the use of an appropriate 
cell line in tissue culture plastics such as culture-
flasks, petri-dishes or cover slips; more than 70% 
of cancer and molecular biologists still rely on this 
technique before progressing to testing in 
animals[31]. However, it is now known that cells 
grown in a 2D environment lack the required 3D 
tissue architecture and cell-to-cell interactions 
experienced in vivo[32]. In addition, cells cultured 
on synthetic plastics and/or non-biological 
substrates have been reported to respond 
differently, as well as not being able to 
elicit/express the correct biological behaviour or 
phenotype appropriate to its characteristic[33, 34]. A 
summary of the differences experienced by cells 
when cultured in a 2D versus a 3D environment is 
shown in Table 2. 
Therefore, a number of 3D methods have been 
accordingly developed over the years to take into 
consideration the spatial organisation of a cell 
within it microenvironment, in an attempt to 
address the missing link between monolayer cell 
culture and in vivo animal use (see reviews by 
Breslin and O’Driscoll, 2013[36]; Knight and 
Przyborski, 2015[37]; Baker and Chen, 2012[23]; 
Haycock, 2011[19]). A list of 3D models currently 
in use for drug toxicity screening is shown in Table 
3. 
 
General problems with scaffolds 
The lack of vascularisation is the major limitation 
of most 3D cell culture models, causing restrictions 
in the diffusion of nutrients and the supply of 
oxygen. This limitation reduces the size of 
engineered tissues, as well as cell viability and 
function[39]. Artificial 3D matrix systems that can 
mimic the ECM have materialised as potential 
strategies towards creating cell culture systems that 
are more realistic.  
The creation of optimised predictive cell 
model systems are needed in pre-clinical drug 
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discovery to improve the current 10% success rate 
in clinical drug testing[40]. 
Additionally, optimised 3D cell culture 
systems are required for tissue engineering[41], 
transplantation[41], and human stem cell biology 
(e.g. induced pluripotent stem cells)[42]. 
 
Biomaterials as scaffolds 
Both synthetic and naturally derived materials are 
currently used to make scaffolds for tissue 
engineering applications[5]. However, the 
development and use of these 3D biocompatible 
scaffolds must overcome several challenges. The 
biomaterials used must be biodegradable, non-
immunogenic, biocompatible, allow for surface 
modifications, and ultimately be cost effective[5]. 
Importantly, the procurement of biological 
scaffolds is often associated with human and/or 
animal derived sources which is disadvantageous 
due batch-to-batch variation, limited donor 
availability, and ethics. A large number of natural 
scaffolds currently in use employ biopolymers that 
can be found in existing ECMs. Examples include 
protein-based materials (e.g. fibrin, collagen, and 
gelatin) and polysaccharide-based materials (e.g. 
alginate, chitosan, glycosaminoglycans, 
hyaluronic acid, and methacrylate)[7-10]. Thus far, 
several cancer models that utilise synthetic 
scaffolds have been created[11], however only a 
small number of 3D models use natural 
materials[12, 13]. Curiously, a multitude of 
biopolymers have thermoresponsive solubility 
behaviour, opening up opportunities to establish 
systems that dissolve or gel at body temperature[14].  
 
Artificial scaffolds vs Decellularised scaffolds 
Two main methods of 3D cell scaffold production 
have been developed. The first method uses 
artificial scaffolds that have been synthesised from 
(bio)polymers. These artificially created scaffolds 
allow for phenomenal control over the material, 
enabling the fine-tuning of the various structural 
and biochemical properties of the scaffold[43-47]. 
The second method, decellularisation, has been 
used to produce natural 3D scaffolds from existing 
tissue[45-51]. The decellularisation process uses a 
range of reagents to lyse the cells and then remove 
them from the ECM of the tissue sample[52, 53]. 
Although this method lacks the precise control 
over the scaffold’s structural and biochemical 
properties, the outcome is an easily obtained, 
naturally derived scaffold that has been used 
repeatedly in the creation of functional organs[49, 50, 
54-56]. 
 
Cross-linking and growth factors  
Cross-linking is the formation of chemical links 
between molecular chains in order to form a three-
dimensional network of connected molecules[57].
 
 
Table 2. Cellular characteristics of cells cultured in a 2D environment compared to a 3D environment (adapted from 
Edmondson et al., 2014[35]) 
Cell characteristic 2D culture environment 3D culture environment 
Cell cycle  
Majority of cells within same stage 
of cell cycle due to uniform 
exposure to stimuli 
Spheroids containing a mixture of cells at 
different stages: proliferating, quiescent, 
hypoxic and necrotic populations 
Exposure to medium and/or drugs Cells experience uniform exposure to medium and/or drugs 
Mass transfer and localised gradients 
limitations for nutrients, growth factors 
and/or drugs. Prone to penetration issues 
and occurrence of necrotic core 
Gene/protein expression 
Often display differential gene and 
protein expression levels compared 
to animal models 
Often display similar gene and protein 
expression levels compared to animal 
models 
Morphology 
Attached and spread cells as a single 
monolayer: stretched sheet-like 
characteristics 
Natural shape as aggregated or 
spheroidal structure  
Proliferation Often faster than in vivo  
May proliferate differently compared to 
2D culture system depending on cell line 
and/or 3D system 
Sensitivity  Frequently succumb to treatment and drugs appear to be very effective 
More resistant than that of 2D culture 
and therefore better predictor of in vivo 
drug responses 
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It is used in tissue engineering to improve the 
mechanical properties of biomaterial scaffolds[58]. 
Cross-linking agents, such as glutaraldehyde, have 
been used to reduce the rate of degradation[2]. 
Biological growth factors are commonly used as 
they encourage the infiltration of cells into the 3D 
scaffold, and also the differentiation into the 
specific cell and tissue type[59]. Commonly used 
growth factors include vascular endothelial growth 
factor (VEGF)[60], bone morphogenetic proteins 
(BMPs)[61], basic fibroblast growth factor (bFGF or 
FGF-2)[62], and transforming growth factor-β 
(TGF-β)[63]. 
 
Artificial scaffold design 
The most commonly used fibre structures created 
for the biomedical industry are knitted, braided, 
woven, and non-woven[64].  
 Knitted structures usually involve the largest 
number of individual fibres, resulting in 
greater intricacy and performance capabilities. 
They are often used when applications will 
undergo lots of stresses and stretching[64]. 
 Braided structures result from the intertwining 
of three or more fibre strands. This allows for 
the creation of flat or hollow structures, which 
have high tensile strength but without a large 
surface area[64].  
 Woven structures can produce a wide range of 
different weaves. These structures are dense 
but light, do not stretch, and are capable of 
retaining their shape, making them ideal for 
supportive functions[64]. 
 Non-woven structures are assembled from 
fibres into complex 3D architectures. These 
structures largely comprise through-pores, 
rather than the blind or closed pores that can be 
found in other types of porous scaffold (Figure 
2). Non-woven structures provide a much 
larger surface area than almost all biomedical 
textiles, and are commonly used as scaffolds. 
This is because they can be customised 
through layer thickness, specific spacing, and 
material integrity to encourage cell growth. 
Previous research has attempted to change the 
porosity in scaffolds produced by 
electrospinning[65-67], but this has been found to 
reduce the mechanical strength[68]. 
 
A major constraint of non-woven scaffold 
fabrication has been the problem of how to 
precisely control the pore size, as well as how to 
create distinct internal channels within said 
scaffold[69]. Formerly, the channelling of porous 
scaffolds with the aim of improving cell 
penetration and the exchange of nutrients and gases 
has been mainly limited to nonfibrous scaffold 
assemblies, such as foam, sponge, and hydrogel 
scaffolds[70-72]. 
 Figure 2: Different pore configurations[73] 
 
Hydrogels 
Hydrogels are water-swollen, cross-linked 
polymer networks[74]. This network of 
interconnected pores allows for the retention of 
high water content, as well as the efficient transport 
of nutrients, oxygen, and waste products[75]. These 
properties make hydrogels an auspicious class of 
materials for 3D cell culture[44, 75-80], and so far, 
both synthetic and natural source hydrogels have 
been used in cell culture[81]. 
 
Polysaccharides 
A multitude of different types of polysaccharides 
have been used as scaffolds for tissue engineering, 
however they usually require a separate cross-
linking step to actually form the hydrogel 
network[82]. 
 
Chondroitin Sulfate 
Chondroitin sulfate (CS) (Figure 3) is a 
glycosaminoglycan (GAG) comprising alternating 
disaccharide units of N-acetyl-D-galactosamine 
and D-glucuronic acid[83]. CS boasts excellent 
biological characteristics[14], although because it is 
readily water-soluble, chemical cross-linking is 
required for in vitro or in vivo use. Most commonly 
used is a mixture of 1-ethyl-3-(3-dimethyl 
aminopropyl) carbodiimide (EDC) and N-
hydroxysuccinimide (NHS)[84]. Unfortunately, 
cross-linking using EDC frequently resulted in 
some collapse of the matrix in aqueous media, 
although this could be prevented to a certain extent 
by cross-linking in the presence of ethanol[85].  
 
 Figure 3. Chemical structure of chondroitin sulfate[14] 
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CS-based hydrogels have found widespread use in 
tissue engineering. Gelatin and CS comprised 
hydrogels have been used to create controlled 
release systems for antibacterial proteins[86]. 
Change et al. used gelatin-CS-hyaluronan 
tricopolymer scaffolds to mimic natural 
cartilage[87, 88]. Bilayer gelatin-CS-hyaluronan 
biomatrices have been investigated for use in 
treating wounds, with the results demonstrating 
that the skin substitute promoted the wound 
healing process and assisted in the regeneration of 
full-thickness skin defects[89, 90]. An overview of 
the biomedical applications of chondroitin sulfate 
is given in Table 4. 
 
Hyaluronic Acid 
Hyaluronic acid (also called hyaluronan, 
hyaluronate, HA) (Figure 4) is the only non-
sulfated GAG, comprising alternating disaccharide 
units of D-glucuronic acid and D-N-
acetylglucosamine, that are linked  together by 
alternating β-1,4 and β-1,3 glycosidic bonds[91, 92]. 
HA is one of the chief components of the 
extracellular matrix in the skin, cartilage, and the 
vitreous humour[93, 94]. 
 
  
Figure 4. Chemical structure of hyaluronic acid[14] 
 
 
HA has been combined with alginate[95], poly-L-
lysine[96-98],  and acrylate-functionalised PEG to 
create different scaffolds for a range of tissue 
engineering applications, including nerve 
regeneration[99] and spinal cord repair[100]. 
Unfortunately, the mechanical properties of the 
previously mentioned HA scaffolds were 
insufficient for use in hard tissue engineering (such 
as cartilage repair). So a number of research groups 
have looked at developing HA-based composites 
that incorporate synthetic polymers such as poly 
lactic-glycolic acid (PLGA)[101] and 
poly(propylene fumarate)[102]. Aside from porous 
HA scaffolds, GAG-based microbeads  and 
nanofibres have been developed using phase 
separation and electrospinning, respectively[14]. 
Additionally, HA and stem cells have been 
combined to serve as injectable material for tissue 
augmentation[103]. An overview of the biomedical 
applications of hyaluronic acid is given in Table 5. 
 
Chitosan 
Chitosan (Figure 5) is the partially deacetylated 
derivative of chitin. This linear polysaccharide 
comprises randomly distributed β-(1-4)-linked N-
acetyl-β-d-glucosamine and D-glucosamine[104], 
and is primarily obtained from the shells of 
crustaceans.  
 
 Figure 5. Chemical structure of chitosan[14] 
 
 
Chitosan microspheres have been created by the 
addition of chitosan solution droplets into a 
solution of sodium tripolyphosphate[105], with the 
goal of developing a chitosan matrix that can be 
used for bone tissue engineering. Chitosan 
scaffolds have been successfully used in tendon 
tissue engineering[106], additionally, scaffolds 
containing elongated channels have demonstrated 
the potential for use in nerve regeneration[107]. 
Different techniques that are used to create porous 
scaffolds include supercritical fluid technology[108, 
109] and stereolithography[110, 111]. Chitosan-based 
scaffolds and nanofibres have been used in bone 
regeneration, either utilising plain chitosan[112, 113] 
or by combining it with synthetic polymers such as 
poly(L-lactic acid)[114], poly(butylene-
succinate)[115],  or with ceramics such as 
hydroxyapatite[116-127]. ECM constituents, such as 
collagen, are frequently incorporated into chitosan-
based scaffolds when being used for tissue 
regeneration[128, 129]. As well as combining 
collagen[130, 131] and its derivatives[120, 132-134] with 
chitosan, synthetic polymers such as poly(ethylene 
glycol)[135, 136] and Pluronics®[137, 138] have also been 
used. Additionally, injectable chitosan-based 
hydrogels have been investigated for their use in 
tissue engineering[139, 140]. An overview of the 
biomedical applications of chitosan is given in 
Table 6. 
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Table 4. Overview of Biomedical Applications of Chondroitin Sulfate[14] 
Type of chondroitin sulfate Application 
gelatin/chondroitin-6-sulfate/hyaluronan, methacrylate- and aldehyde-modified 
chondroitin sulfate, chondroitin sulfate/chitosan/dermatan sulfate, poly(L-lactide)-g-
chondroitin sulfate, poly(ethylene glycol)/chondroitin sulfate 
 
Cartilage 
EDC cross-linked chondroitin sulfate/collagen/elastin, EDC cross-linked chondroitin 
sulfate/collagen, thiolated chondroitin sulfate/hyaluronan/gelatin 
General tissue 
engineering 
application 
chondroitin sulfate/collagen Heart 
gelatin/chondroitin-6-sulfate/hyaluronan, glutaraldehyde cross-linked gelatin/chondroitin-
6-sulfate Intervertebral disc 
chondroitin sulfate/heparin/collagen Liver 
chondroitin sulfate/collagen Lung 
EDC cross-linked chondroitin-6-sulfate/gelatin/hyaluronan Skin 
chitosan/chondroitin sulfate, chondroitin sulfate/Pluronic F127 nanogel, chondroitin 
sulfate spheres Drug release 
 
  
Table 5. Overview of Biomedical Applications of Hyaluronic Acid[14] 
Type of hyaluronic acid Application 
ester-containing hyaluronic acid Adipose tissue 
amine/aldehyde-containing hyaluronic acid, hyaluronic acid/poly(vinyl alcohol), MMP-sensitive 
hyaluronic acid Bone 
hyaluronic acid/collagen I, hyaluronan/gelatin/chondroitin-6-sulfate, 
adipic dihydrazide-modified collagen/hyaluronic acid, fibrin/hyaluronic acid, chitosan/hyaluronic 
acid, carrageenan/fibrin/hyaluronic acid 
Cartilage 
thiolated hyaluronan/poly(ethylene glycol) diacrylate, hyaluronic acid/gelatin gradient, 
poly(N-isopropylacrylamide)/hyaluronic acid, hyaluronic acid/pendant L-benzoyl-cysteine, 
methacrylated hyaluronic acid, collagen/hyaluronan/chitosan, collagen/hyaluronic acid, silk 
fibroin/hyaluronan 
General 
acryl-modified hyaluronic acid/poly(ethylene glycol) acryl Gene therapy 
ester-containing hyaluronan/butyric and retinoic acid, methacrylated hyaluronan, 
divinyl sulfone cross-linked hyaluronan Heart 
benzyl esters of hyaluronic acid, hyaluronan/gelatin/chondroitin-6-sulfate Intervertebral disc 
benzyl esters of hyaluronic acid Liver 
hyaluronic acid Muscle 
photo-cross-linked hyaluronic acid, collagen/hyaluronic acid, fibroin/hyaluronic acid, 
antibody-modified hyaluronic acid, hyaluronic acid/polylysine Nerve 
hyaluronic acid derivatives, carbodiimide-cross-linked hyaluronic acid Ophthalmology 
benzyl esters of hyaluronic acid, hyaluronan-gelatin, 
EDC cross-linked hyaluronan/chondroitin-6-sulfate/gelatin, 
adipic dihydrazide derivatives of hyaluronic acid/PEG-propiondialdehyde, hyaluronic 
acid/chitosan/gelatin 
Skin 
thiol-modified hyaluronic acid Spinal cord 
methacrylated hyaluronic acid Vascular tissue 
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Table 6. Overview of Biomedical Applications of Chitosan[14]
Type of chitosan Application 
glutaraldehyde-cross-linked collagen/chitosan Adipose tissue 
freeze-dried chitosan/gelatin, electrospun collagen/chitosan nanofibre Blood vessel 
sintered chitosan microspheres, poly(ε-caprolactone)/poly(vinyl alcohol)/chitosan, 
chitosan/fibroin/hydroxyapatite, β-TCP/chitosan, β-FGF-loaded hydroxyapatite/chitosan, 
polycaprolactone/chitosan, chitosan/alginate multilayer scaffold, chitosan/gelatin, 
titania/chitosan composite, photo-cross-linkable chitosan, chitosan/collagen, ceramic 
nanoparticles/chitosan, 
chitosan/polyethylene glycol dimethacrylate/N,N-dimethylacrylamide, silk/chitosan, 
nanohydroxyapatite/chitosan/carboxymethyl cellulose 
Bone 
chitosan beads, EDC-cross-linked collagen/chitosan/GAG, chitosan/poly(butylene succinate), 
CS/dermatan sulfate/chitosan, chitosan/hyaluronic acid, chitosan/polyester-based, insulin-
loaded chitosan, chitosan/gelatin, alginate/chitosan, chitosan/gelatin/hyaluronan, 
chitosan/Pluronic, 
polyethylene oxide/chitosan, glutaraldehyde/oxidised dextran/chitosan 
Cartilage 
hydroxypropyl chitosan/gelatin Corneal stroma 
chitosan/starch, hydroxyapatite/chitosan, chitosan/soy protein/TEOS, 
collagen/hyaluronan/chitosan, 
genipin-cross-linked chitosan, thiolated chitosan, electrosprayed chitosan microbeads,  
chitosan/poly(vinyl alcohol), poly(caprolactone)/chitosan, chitosan/collagen, 
nanofibrous PLLA/chitosan fibres, disulfide cross-linked chitosan, chitosan/poly-L-lysine, 
chitosan/gelatin, chitosan-graft-β-cyclodextrin, calcium phosphate/chitosan, carboxymethyl 
chitosan-graft-D-glucuronic acid, chitosan/PEG/gelatin, chitosan-g-lactic acid, 
chitosan/phospholipid 
General tissue 
engineering 
applications 
chitosan/glycerophosphate, chitosan/glycerophosphate/hydroxyethyl cellulose Intervertebral disc 
collagen/chitosan, silk fibroin/chitosan/heparin, chitosan/gelatin Liver 
alginate dialdehyde cross-linked chitosan/calcium polyphosphate Meniscus 
poly(lysine)-functionalised chitosan, polypyrrole/chitosan, PLGA/chitosan/HA, 
chitosan/polyglycolic acid Nerve 
chitosan/gelatin/glycerol phosphate Nucleus pulposus 
DTBP-cross-linked chitosan, gold colloid/chitosan, collagen/chitosan, bFGF/chitosan, 
β-glycerol phosphate/collagen/chitosan Skin 
chitosan-based hyaluronan, chitosan microchannel Tendon 
 
 
Cellulose Derivatives 
Cellulose (Figure 6) is an organic polysaccharide 
comprising D-glucose subunits linked together by 
β(1–4) glycosidic bonds[141]. It is also the major 
structural component of plant cell walls. Unlike 
starch and glycogen, minimal nutritional benefit 
can be obtained from cellulose because the 
glycosidic bonds can only be digested by the 
enzyme cellulase[5]. 
   
Figure 6. Chemical structure of methyl cellulose (left) 
and (hydroxypropyl)methyl cellulose (right)[14] 
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Native plant derived nanofibrillar cellulose has 
been used in hepatocyte 3D cell culture[81], but it is 
not commonly used in the field of tissue 
engineering. This is possibly due to the difficulty 
of isolating the nanofibres from the plant cell 
walls[142-144]. Alternatively, synthetically produced 
cellulose scaffolds have seen use in a wide variety 
of 3D mammalian cell culture[17, 145-148], including 
being combined with hydroxyapatite for use in 
bone tissue engineering[122, 149-152]. Cellulose is also 
frequently combined with proteins[153], 
polysaccharides[154], or both[122, 155]. 
Bacterial cellulose has been used for a variety 
of tissue engineering purposes[149, 156-158], including 
hard tissue such as bone and cartilage[78, 159], 
because it has been reported that bacterial cellulose 
supports the proliferation of mammalian cells[160-
162]. Unfortunately, bacterial cellulose cannot be 
enzymatically degraded in vivo, resulting in the 
necessary production of modified bacterial 
cellulose[163, 164]. At the present time it is premature 
to speculate on the suitability of bacterial cellulose 
as implantable scaffolds, because there are 
unknowns about their in vivo biocompatibility. The 
immunogenicity and abiding stability of implanted 
cellulose-based biomaterials is still under 
investigation[156, 160]. An overview of the 
biomedical applications of cellulose derivatives is 
given in Table 7. 
 
Alginate 
Alginate is a polysaccharide, comprising units of 
β-D-mannuronic acid and α-L-guluronic acid[165], 
that is found in the cell walls of brown algae. 
Alginate has shown its usefulness for  tissue 
engineering as it is mucoadhesive, biocompatible, 
and non-immunogenic[166]. Even though it does not 
naturally possess cell interactive properties, 
numerous compounds including proteins[167, 168] 
and cell-interactive peptides or growth factors[169] 
have been coupled to the alginate backbone to 
overcome this problem[170]. Alginate is also 
frequently combined with calcium phosphates for 
use in bone tissue engineering[167, 171, 172]. Alginates 
are showing promise in the field of pharmaceutics 
because of their propensity to form an ionotropic 
gel after the addition of multivalent cations[170, 173]. 
An overview of the biomedical applications of 
alginates is given in Table 8. 
 
Proteins 
Collagen 
Collagen is the main structural protein of the ECM, 
and is the most abundant protein in vertebrates[174], 
with more than 12 types of collagen found across a 
variety of tissues[175-183]. The majority of porous 
collagen-based scaffolds are made using 
stereolithography  or freeze-drying, although a 
novel technique for the cryogenic plotting of 3D 
scaffolds has been developed[184]. Specific scaffold 
designs and methods have been used for specific 
tissue regeneration purposes. Examples include 
cylindrical tubes for use in blood vessel 
regeneration made using a rotating cylinder[185], 
and nanofibres created using electrospinning[186-
192]. 
For use in bone tissue regeneration, calcium 
phosphates are often combined with the porous 
collagen scaffold[193-199]. Additionally, multiple 
researchers have developed composite scaffolds 
with synthetic polymers[200-205], or modified 
GAGs[197, 206-211], to form semi-interpenetrating 
polymer networks (SIPN)[212, 213]. As with alginate, 
the cell-interactive properties of the collagen-based 
matrices have also been improved, with specific 
peptides[214], growth factors [215-218], or both having 
been incorporated into the matrix.  Recombinant 
human-like collagen has been developed with an 
eye towards safety issues, such as the risk of 
pathogen transmission from animals to humans[131, 
219, 220]. An overview of the biomedical applications 
of collagen is given in Table 9. 
 
 
Table 7. Overview of Biomedical Applications of Cellulose Derivatives[14] 
Type of cellulose Application 
Ca2+-activated cellulose, cellulose/lactide, bacterial cellulose, nanohydroxyapatite/bacterial 
cellulose Bone 
cellulose/collagen, injectable cellulose Cartilage 
bacterial cellulose Cornea 
various cellulose-based hydrogels General 
cellulose acetate and regenerated cellulose Heart 
bacterial cellulose Muscle 
cellulosic hydrogels Nerve 
carboxymethyl cellulose Nucleus pulposus 
bacterial cellulose Vascular 
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Table 8. Overview of Biomedical Applications of Alginate[14]
Type of polymer Application 
alginate/elastin/PEG, angiogenic factors/alginate Blood vessel 
alginate microbeads, alginate/gelatin/hydroxyapatite, oxidised alginate/gelatin/tricalcium 
phosphate, chitosan/alginate, alginate/poly (lactic-co-glycolic acid)/calcium phosphate, 
collagen/alginate/nanohydroxyapatite 
Bone 
sodium alginate, chitosan/alginate, gelatin/alginate Bone marrow 
alginate/fibrin, agarose/alginate/gelatin, chitosan/alginate/hyaluronate, PLGA/alginate, 
transforming growth factor-β(1) loaded alginate Cartilage 
alginate, alginate-cis-aconityl-daunomycin, calcium alginate/silk fibroin, hyaluronic 
acid/alginate, PLGA/Ca-alginate Drug delivery 
alginate, alginate/poly(vinyl alcohol), laminated alginate, carbon nanotube/alginate, iron-
cross-linked alginate, 
alginate/poly(L-lysine)-hyaluronic acid, alginate/chitosan, copper-capillary alginate 
General 
injectable alginate, gelatin/alginate Heart 
alginate/chitosan Ligament 
macroporous alginate, alginate/galactosylated chitosan, sodium alginate Liver 
chitosan/calcium polyphosphate Meniscus 
photo-cross-linked alginate Nucleus pulposus 
gelatin/alginate Skin 
alginate Spinal cord 
alginate/chitosan Tendon 
 
 
Table 9. Overview of Biomedical Applications of Collagen[14]
Type of polymer Application 
glutaraldehyde-cross-linked collagen/chitosan, bFGF/collagen, collagen microbeads Adipose tissue 
compressed collagen Bladder 
collagen/cell assembly, p(DLLA-co-TMC)/collagen, collagen-chitosan nanofibre, PLGA 
microsphere/collagen, fibroin/collagen, TMC/DNA-containing collagen, collagen/citric acid 
derivative, polylactide/silk fibroin/gelatin 
Blood vessel 
collagen/nanohydroxyapatite, dense collagen, polyvinyl alcohol/collagen/hydroxyapatite, collagen 
microspheres, 
collagen/nanotube, collagen I/PLGA-β-TCP, collagen fibre/PLA, collagen/glycosaminoglycan, 
nano-HA/collagen/PLLA, collagen/OP-1, PCL/collagen, RhBMP-2 
microspheres/chitosan/collagen, 
adenovirus vectors/collagen/chitosan 
Bone 
collagen/chitosan/GAG, adipic dihydrazide-modified collagen/hyaluronic acid, PLGA/collagen, 
micronised collagen sponges, type II collagen, collagen propeptides, 
type II collagen/chondroitin sulfate/hyaluronan, collagen/HA/chondroitin sulfate 
Cartilage 
dendrimer-cross-linked collagen, hydroxypropyl chitosan/gelatin Cornea 
CO(3)Ap-collagen Dental 
photo-cross-linked collagen, EDC-cross-linked electrospun collagen, poly(lactic-co-glycolic 
acid)/collagen, PHBV/collagen, collagen/hyaluronan/chitosan, collagen/hyaluronic acid, 
TPU/collagen, collagen/glycosaminoglycan, poly(lactic acid-co-caprolactone)/collagen,  
stromal cell-derived factor 1α-loaded heparinised collagen, collagen/hyaluronan/chitosan, 
gelatin/alginate 
General 
type I collagen, collagen/GAG Heart 
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Table 9. Continued….. 
 
 
type I and II collagen/GAG Intervertebral disc 
collagen/silk Ligament 
poly(lactic-co-glycolic acid)/collagen, collagen/chitosan/heparin Liver 
cross-linked atelocollagen Muscle 
collagen/microchannels, collagen/hyaluronic acid, collagen/heparan sulfate Nerve 
collagen II/hyaluronan/chondroitin-6-sulfate, collagen Nucleus pulposus 
UV-cross-linked collagen Ophthalmology 
PLGA/collagen Pancreas 
compressed collagen, cross-linked collagen/chondroitin sulfate/hyaluronic acid, 
β-glycerol phosphate/collagen/chitosan, collagen/elastin, electrospun collagen/PCL, 
poly[(D,L-lactide)-co-glycolide]/collagen 
Skin 
collagen Urological 
 
 
Gelatin 
Gelatin is a soluble protein produced by the partial 
hydrolytic degradation of collagen. The primary 
sources of gelatin are pig skin (46%), cow hide 
(29.4%), and pork and cattle bones (23.1%)[221]. 
Gelatin is frequently used for biomedical 
applications because of its wide variety of 
chemical properties, such as gel formation, shear 
thickening, protective colloid function, and film-
forming capacity[222]. As gelatin has a sol-gel 
transition temperature of approximately 30°C, it 
must be chemically cross-linked in order to prevent 
dissolution at body temperature.  As a result of the 
number of side chains present in gelatin, a wide 
array of modification methods could be used[223, 
224]. However, the chosen reagents must be water-
stable as gelatin will only dissolve in water and 
some alcohols. Cross-linking reagents that have 
been used include glutaraldehyde[225], 
carbodiimides[226], diisocyanates[227, 228], polyepoxy 
compounds (PCs)[229], genipin[230-232], and acyl 
azides[233]. 
Created using cryogenic treatments and 
lyophilisation[234-236], gelatin combined with 
methacrylamide has been used to produce porous 
scaffolds that support the adhesion, spreading, and 
proliferation of human cells (endothelial cells, 
fibroblasts, epithelial cells, glial cells, and 
osteoblasts)[237]. More common techniques used to 
produce porous gelatin-based scaffolds for tissue 
engineering are freeze-drying and phase 
separation[236, 238, 239]. Since gelatin is derived from 
collagen, it is commonly combined with calcium 
phosphates[240-244] and/or GAGs[89, 90, 245-247] when 
targeting specific tissues. An overview of the 
biomedical applications of gelatin is given in Table 
10. 
 
Elastin 
Elastin is a major component of mechanically 
active tissues that require elasticity, such as lungs, 
arteries, skin, and elastic ligament and 
cartilage[248]. Commercially available dermal skin 
substitutes comprising elastin and collagen (such 
as MatriDerm® and AlloDerm®) have frequently 
been evaluated for their uses in wound healing[249-
251]. Because of the vast amount of covalent cross-
linking present in native elastin, it is not commonly 
used as cell carriers for tissue engineering[252]. 
However, modified elastin has been used to create 
porous scaffolds using CO2[253], as well as 
nanofibres made by electrospinning[254-258]. 
Additionally, elastin-like polymers demonstrate 
excellent biocompatibility as they are similar to 
natural elastin and their degradation products are 
native amino acids[259]. An overview of the 
biomedical applications of elastin is given in Table 
11. 
 
Fibroin 
Fibroin is a naturally-produced hydrophobic 
glycoprotein synthesised by spiders, as well as 
numerous insects, including the silkworm Bombyx 
mori[260]. The primary structure of fibroin almost 
entirely consists of the recurrent amino acid 
combination (Gly-Ala-Gly-Ala-Gly-Ser)n[166]. Silk 
fibroin shows remarkable promise as a material for 
implantation as it is tissue compatible, minimally 
immunogenic, and non-toxic[261]. Additionally, 
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silk-based biomaterials are biocompatible with 
numerous cell types, able to promote successful 
cell growth and proliferation[262-264]. Silk fibroin 
can be processed into a wide array of different 
forms including films[265-267], gels[268, 269], 
nanofibres[270-274], scaffolds[275], membranes[276], 
hydrogels[277, 278], nanoparticles[277, 279, 280], and 
powders[281, 282]. This versatility makes it extremely 
useful to the field of biomaterials and drug 
delivery[166]. To produce different scaffolds, fibroin 
has been combined with gelatin for ligament tissue 
engineering[239], hydroxyapatite for bone tissue 
engineering[283, 284], as well as other proteins[189, 219, 
285, 286] and glycosaminoglycans[287, 288]. An 
overview of the biomedical applications of fibroin 
is given in Table 12. 
 
Summary of desired scaffold properties 
Scaffolds for tissue engineering need to support 
cell growth in three dimensions in order to be 
successful. The most effective scaffolds have a 
surface area large enough for cell attachment, and 
are highly porous in order to facilitate continuous 
nutrient diffusion[289]. Scaffolds can be created 
using a range of different methods and techniques, 
including dissolvable porogen-fused scaffolds, 3D 
printing, laser-sintering, as well as electrospun 
fibres, hydrogels and nonwovens[290]. The 
materials that are used to create the scaffold must 
be biocompatible and, if required, degradable. 
Especially important in bone tissue and ligament 
formation, until the new tissue becomes load 
bearing, the porosity of the scaffold must not 
compromise its mechanical performance[291]. 
 
Table 10. Overview of Biomedical Applications of Gelatin[14] 
Type of polymer Application 
gelatin sponge Adipose tissue 
gelatin/poly(ε-caprolactone) nanofibres, VEGF immobilised gelatin, polyethylene-glycol 
diacrylate/gelatin, chitosan/gelatin, gelatin/PET nanofibres, gelatin/PES fibres, gelatin/PTFE Blood vessel 
hydroxyapatite chitosan/gelatin, gelatin/poly(α-hydroxy acids), glutaraldehyde cross-linked 
gelatin, hydroxyapatite/gelatin, β-tricalcium phosphate/gelatin, gelatin/poly(ε-caprolactone) 
nanofibres, 
gelatin microcarriers/polyester, micro- and nano-hydroxyapatite/chitosan/gelatin, 
rhBMP-2-loaded gelatin/nano-hydroxyapatite/fibrin, 
poly[(L-lactide)-co-(epsilon-caprolactone)]/gelatin, gelatin-based photopolymers 
Bone 
gelatin/chondroitin-6-sulfate/hyaluronan, plasmid DNA/chitosan/gelatin, gelatin 
microparticle/OPF, 
gelatin microparticle/poly(D,L-lactide-ε-caprolactone), TGF-β1-loaded gelatin, 
ceramic/gelatin, 
esterified hyaluronan/gelatin, gelatin/chitosan/hyaluronan 
Cartilage 
transglutaminase cross-linked gelatin, proanthocyanidin cross-linked chitosan/gelatin, 
gelatin/poly(D,L-lactide), gelatin fibres, PHBHHx/gelatin, PVA/gelatin, PNIPAM/gelatin, 
gelatin- and fibronectin-coated PE multilayer nanofilms, gelatin/montmorillonite/cellulose, 
chitosan/PEG/gelatin, gelatin/(hydroxyphenyl)propionic acid, gelatin microparticles, 
gelatin/chitosan cryogels, genipin-cross-linked PCL/gelatin nanofibres, silk sericin/gelatin, 
α-chitin/gelatin, agarose/gelatin cryogel, hyaluronan/gelatin 
General 
gelatin/polyurethane, photo-cross-linked gelatin, alginate/gelatin Heart 
gelatin/chondroitin-6-sulfate/hyaluronan, gelatin, glutaraldehyde cross-linked 
gelatin/chondroitin-6-sulfate 
Intervertebral 
disc 
gelatin/silk fibroin Ligament 
cross-linked sodium alginate/gelatin, chitosan/gelatin Liver 
gelatin/PCL nanofibres Muscle 
photo-cross-linkable gelatin, gelatin/(hydroxyphenyl)propionic acid Nerve 
chitosan/gelatin/glycerol phosphate Nucleus pulposus 
gelatin/agarose Pancreas 
glutaraldehyde cross-linked gelatin Skin 
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Table 11. Overview of Biomedical Applications of Elastin[14]
Type of polymer Application 
collagen/elastin, alginate/elastin/PEG, collagen/elastin/PCL, copper non-parasitic/elastin, 
bFGF/elastin, polydioxanone/elastin/collagen, poliglecaprone/PCL/elastin/gelatin, 
polyglyconate/elastin 
Blood vessel 
BMP-containing elastin Bone 
hexamethylene diisocyanate-cross-linked α-elastin, recombinant elastin, tropo-elastin, 
collagen/elastin, collagen/elastin/chitosan/poly(lactic acid), poly(lactide-co-
glycolide)/gelatin/elastin 
General 
elastin-like proteins Nerve 
recombinant elastin Ocular 
collagen/elastin Skin 
 
Table 12. Overview of Biomedical Applications of Fibroin[14] 
Type of polymer Application 
non-mulberry and mulberry silk gland fibroin Adipose tissue 
fibroin, collagen/fibroin, polylactide/silk fibroin-gelatin, fibroin modified-polyhydroxyalkanoate Blood vessel 
silk fibroin/chitosan/PLLA, chitosan/fibroin-hydroxyapatite, non-mulberry silk gland fibroin, 
non-mulberry and mulberry silk gland fibroin Bone 
silk fibroin modified porous poly(e-caprolactone), plasma-treated fibroin Cartilage 
alginate/fibroin, silk fibroin/gelatin Drug delivery 
gelatin/silk fibroin, hyaluronan/silk fibroin, chitosan/silk fibroin, fibroin/recombinant human-like 
collagen, 
Antheraea assama silk fibroin, nano-hydroxyapatite/fibroin, silk fibroin-modified PHBHHx, 
polylactide/silk fibroin-gelatin 
General 
gelatin/silk fibroin Ligament 
fibroin/recombinant human-like collagen, PLLA/fibroin, chitosan/silk fibroin, chitosan/silk 
fibroin/heparin Liver 
Antheraea pernyi silk fibroin Tendon 
 
 
Why animals are used? 
History of animal testing 
Experiments on animals have been performed 
since the inception of biomedical research. Starting 
with Greek physician-scientists, such as Aristotle 
(384–322 BC) and Erasistratus (304–258 BC), 
experiments have been carried out on living 
animals to advance our knowledge and 
understanding of anatomy, physiology, pathology, 
and pharmacology[292]. Today, animal testing is 
used for a variety of purposes, including tests on 
drug activity and affinity[293], toxicological 
screenings, vaccines[294, 295], and as tools to 
understand the effects of medical procedures and 
surgical experiments[296]. 
The importance of drug testing using animals 
became apparent in the 20th century with a variety 
of famous, and tragic, cases of drug toxicity. In 
1937, an American pharmaceutical company made 
a preparation of the antibiotic sulfanilamide, and 
used diethylene glycol as the solvent. 
Unfortunately, diethylene glycol is toxic to 
humans, and the subsequent mass poisoning 
caused the deaths of one hundred and five patients. 
This, and similar, incidents resulted in the creation 
of the 1938 Federal Food, Drug, and Cosmetic Act, 
which required drug toxicity testing on animals 
before they could be marketed[297]. 
Another drug-related tragedy occurred in the 
1950s-1960s with thalidomide. Originally 
marketed as a tranquilliser and painkiller, 
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thalidomide was discovered to prevent morning 
sickness, consequently thousands of pregnant 
women took thalidomide to relieve their 
symptoms. As a result of thalidomide’s 
teratogenicity, more than 10,000 children across 46 
countries were born with malformations or missing 
limbs (phocomelia)[292]. Confusingly, rodents used 
in the original thalidomide toxicity studies did not 
display signs of teratogenicity. However, 
subsequent research has demonstrated that rats are 
thalidomide-resistant, compared to rabbits which 
are thalidomide-sensitive[298]. After thalidomide it 
was recognised that inter-species differences 
required consideration. This produced the 
requirement that developmental toxicity testing for 
pharmaceuticals is performed using two different 
animal species, one of which is not a rodent[296]. 
 
Numbers of animal testing 
Each year, millions of animals are used across the 
world in toxicity testing and biomedical research, 
with the focus on developing cures for human 
diseases. It is estimated that 17.3 million animals 
were used in 2005, making the United States the 
leading global user with 1.2 million. Japan was 
second with 11.2 million, and China third with 3.0 
million animals used[299]. In 2013, 4.12 million 
scientific procedures were carried out in Great 
Britain, an increase of 11,600 compared to 
2012[300], with mice, fish, and rats the most 
commonly used species (Figure 7).  
 
 Figure 7. Procedures by species of animal, 
2013[300] 
 
In Great Britain, in 2013, the number of animal 
procedures used for toxicity testing decreased by 
0.5% to 375,000. In contrast, the number of non-
toxicity procedures increased by 0.4% to 3.75 
million. These non-toxicity-based procedures 
cover the breeding of genetically modified animals 
(GM), and animals with harmful genetic mutations 
(HM), for research. The main fields of research 
were immunology, cancer research, physiology, 
anatomy, and genetics[300]. 
 
Procedures within animal testing 
The term ‘regulated procedure’ refers to any act, 
carried out for a scientific purpose, that may cause 
an animal a greater level of pain, suffering or 
distress than would be caused by the insertion of a 
hypodermic needle[301]. A procedure can be as mild 
as an injection, or as severe as an organ 
transplant[302]. Procedures are classified as ‘non-
recovery’, ‘mild’, ‘moderate’, or ‘severe’ on a 
case-by-case basis,  based upon the degree of pain, 
suffering, distress, or lasting harm that will be 
experienced by the animal[303]. 
Non-recovery procedures are performed under 
permanent general anaesthetic, with the animal 
being euthanised when the procedure is 
finished[303], an example being to make a hole in 
the intestines of an animal to cause sepsis in order 
to monitor the effects[304]. Mild procedures result in 
an animal being likely to experience short-term 
mild pain/suffering/distress[303], such as from 
short-term social isolation or superficial surgical 
procedures[305]. Moderate procedures result in an 
animal being likely to experience short-term 
moderate pain/suffering/distress, or long-lasting 
mild pain/suffering/distress. They may also 
undergo procedures that are likely to cause 
moderate impairment of their well-being or general 
condition[303]. This can include organ 
transplantation or exposing the animal to a fearful 
stimulus whilst restraining[306]. Severe procedures 
result in an animal being likely to experience 
severe pain/suffering/distress, or long-lasting 
moderate pain/suffering/distress. They may also 
undergo procedures that are likely to cause severe 
impairment of their well-being or general 
condition[303]. This can include inescapable electric 
shocks, or any tests that deliberately result in 
death[307]. 
 
The Draize test 
One of the most famous, and arguably most 
controversial, testing methods is the “Draize test”. 
Devised in 1944 by US Food and Drug 
Administration (FDA) toxicologist John Draize, 
the procedure was initially used for assessing the 
damage caused by acute, intermediate, and chronic 
exposure of cosmetic-based compounds to the 
skin, penis, and eyes of rabbits[308]. Subsequent to 
Draize’s initial publication, the FDA used the 
aforementioned techniques to assess the safety of 
several substances, such as insecticides, 
sunscreens, and antiseptics[309]. The method used 
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by Draize was widely adopted, with scientists 
referring to this method simply as the ‘Draize 
technique’ or the ‘Draize test’[310]. However, 
despite its widespread adoption and “gold 
standard” status, Draize testing was never formally 
validated[311]. Somewhat ironically, the original 
reason for devising methods to test for ophthalmic 
toxicity was not to screen medications for public 
safety. Instead it was with the aim of identifying 
chemicals that could be weaponised to harass, 
harm, and blind enemy soldiers[312]. 
 
Animal testing controversy 
The continual increase in the use of GM and HM 
animals, as well as a number of large-scale 
chemical testing programs operating within the US 
and Europe, are causing an increase in the number 
of animals used in laboratory experiments[313]. Yet 
biomedical research using animals remains a 
highly controversial and emotive subject. 
Proponents often claim that research involving 
animal testing is vital for preventing, relieving, or 
curing human diseases[314, 315], that the most notable 
medical achievements have only been possible 
because of animal testing[316], and that the 
physiological and biological complexity of humans 
requires the use of animal models in order to 
successfully interpret the results of biomedical 
investigations[317].  
However, such claims are hotly contested[318-
320]. Whilst segments of the animal rights 
community have long challenged the merit of 
preclinical studies that use animals as barometers 
for human response, recently the worth of animal 
studies has been questioned by the scientific 
community itself[321-323]. An increasing catalogue 
of evidence questions the validity of animal studies 
as experimental human models[324-327], with the 
lack of consistency of animal efficacy data with the 
outcomes of human trials resulting in questions 
over the fundamental role that animal-based 
studies have in preclinical studies[328-330], and the 
methods used within[331, 332].  
Animal experiments commonly used as part of 
pharmaceutical research suffer from varying 
degrees of success, as the translation from animal 
to human depends upon the parameter being tested. 
For example, converting oral drug bioavailability 
from animal data to humans is a classic failure as 
no acceptable correlation between species has ever 
been identified[333]. Another example is that the 
volume of drug distribution between humans and 
animals is broadly similar, whereas predicting the 
drug distribution to individual cell types/tissues is 
more difficult[334]. Olson et al. reported that 
approximately 50% of the drugs that are 
acknowledged to cause human liver injury were 
not recognised as hepatotoxic by the animal 
testing[335]. This lack of concordance is probably 
caused by the significant differences in liver 
pathways between animals and humans[336-338]. 
Aside from the ethical concerns, drawbacks of 
animal testing include the required skilled/trained 
manpower, time consuming protocols, and the high 
cost of breeding and housing[339]. 
 
Alternatives to animal testing 
The experimental protocols involved in animal 
testing have remained comparatively unchanged 
for over 40 years[340], yet consumers constantly 
expect greater safety and information about their 
products. Across the world, approximately £10 
billion a year is spent on animal experiments, of 
which about £2 billion is spent on toxicology 
studies[340]. The costs of using, housing, and 
maintaining the vast numbers of animals required 
for use in the toxicity testing of a single compound 
can exceed millions of pounds[339, 341]. A number of 
ethical, business, and legal concerns, as well as 
continual scientific advances, have driven the 
demand for alternative, animal-free testing that is 
more accurate and relevant to humans[342]. 
Across Europe, there has been a political shift 
in the attitude about animal testing, moving 
towards testing methods that use animals 
minimally, if at all. Since implementing the 
Animal Welfare Guideline 86/609/EC in 1986, it is 
the policy of all European Union institutions to 
support the development and use of alternative 
testing methods[343]. Animal testing on cosmetic 
ingredients  has been completely banned in Europe 
since March 2009[344]. Additionally, current 
European Union chemicals legislation 
(Registration, Evaluation, and Authorisation of 
Chemicals - REACH) recommends animal testing 
only as a last resort, when there is an absence of in 
vitro or in silico alternatives[345-347]. 
More effort has been spent on producing viable 
alternative testing techniques to the Draize test 
than all other in vivo toxicity tests combined[348]. 
Opponents of the Draize eye and skin irritation 
tests often cite its subjective and time-consuming 
nature[349], variable estimates[311, 350], insufficient 
relevance of test chemical application[341], high 
doses[351], non-standardised test methods[352], and 
over-prediction of human responses[353].  
Interspecies differences are the main source of 
over-predicting human response from the Draize 
test[354], such as rabbit skin being much more 
reactive than human skin[355], and the anatomy of 
rabbit eyes differing quite substantially from 
human eyes. Compared to humans, rabbit corneas 
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are thinner, produce fewer tears, blink less often, 
their ocular surface is less sensitive[348], they have 
larger conjunctival sacs, and they have a third 
eyelid[356]. A suggested “gold standard” alternative 
to the Draize test for eye irritation would be the 
human response[357], using a testing strategy that 
uses a very large number of humans in order to 
fully represent human diversity. The test subjects 
would be unknowingly (“blinded”, if you will) 
exposed to the substance and the effects 
assessed[340]. Many research articles that engage 
with members of the public produce the suggestion 
of using convicts, usually limited to murderers and 
paedophiles, as an alternative to animal testing[358]. 
However, because such experimentation is 
unrealistic and unethical, human data can only be 
obtained from accidental exposure or clinical 
studies. 
To overcome some of the problems associated 
with animal testing, and to avoid unethical 
procedures, a strategy of 3R’s (reduction, 
refinement, and replacement) is applied to find 
more palatable alternatives[359].  This strategy 
encourages the use of minimal animals in an 
experiment, with their use carefully planned and 
streamlined to minimise pain and distress, and 
conscious living vertebrates should be substituted 
with alternative methods and lower organisms[339, 
359, 360]. 
A variety of different models have been 
suggested as alternatives to animal testing, these 
models include; 
 
 Computer models 
Computational models and simulations are 
used for the toxicity testing of chemicals and 
potential drug candidates, without the need for 
animal testing. Only the most auspicious 
molecules are carried forward for use in in vivo 
experiments[361]. Computer Aided Drug 
Design (CADD) can predict the likely binding 
sites for potential drug molecules, preventing 
the testing of compounds with no biological 
activity. Drug molecules can also be designed 
for a specific binding site, with animal testing 
performed to corroborate the results[362]. 
Structure Activity Relationships (SARs) 
predict the biological activity, such as 
carcinogenicity and mutagenicity, of a drug 
candidate based upon its molecular 
structure[363]. The benefits of computer models 
are their greater speed over conventional 
animal models, with the procedures used being 
relatively inexpensive[364]. 
The sheer complexity of producing QSAR 
software can give rise to multiple factors that 
contribute to the relatively poor performance 
of QSAR software in predicting the 
carcinogenic potential of pharmaceuticals. 
These include the inadequate representation of 
the molecular diversity of drugs, and of the 
biological and toxicological complexity of 
chemically-induced carcinogenicity, as well as 
the SAR evaluation criteria itself. Yet despite 
these hurdles, more-recent QSAR databases 
have demonstrated their effectiveness in 
predicting the carcinogenicity of test 
compounds, with one study describing a 
QSAR system that demonstrated 97% 
sensitivity for rodent carcinogens and 98% 
specificity for non-carcinogens[364]. 
 
 Cells and tissue cultures 
The use of in vitro cell and tissue culture 
involves the removal of cells and tissues from 
an animal source, and their subsequent growth 
as a monolayer or in suspension. Cell and 
tissue culture methods are commonly used for 
the initial screening of potential drug 
molecules or chemicals in order to investigate 
toxicity, efficacy, drug disposition, drug-drug 
interactions (DDIs), drug clearance, and major 
metabolites[365-368]. The benefits associated 
with cell and tissue culture testing are that the 
protocols are simpler, quicker, and cheaper 
than directly testing on animals[369-371], with 
toxicity able to be understood at the cellular or 
molecular level[341]. However, in vitro cell and 
tissue culture experiments cannot always 
reliably predict the in vivo properties of 
compounds, as a multitude of important 
biological factors cannot be adequately 
replicated in vitro[372].  
An alternative to the Draize test for ocular 
chemical irritancy has been proposed, one 
which uses bovine corneal organ culture in 
vitro. However, there are some inherent 
differences between the two models, such as 
layers of mucin and epithelium in the cornea, 
which form a highly impermeable line of 
defense against biological and chemical 
insults[373]. 
The haemoglobin denaturation (HD) test, 
where the denaturation of haemoglobin by 
surfactants is evaluated, has been developed to 
predict the eye irritation potential of 
chemicals[374]. The in vitro test results are 
reported to be in good agreement with the 
Draize test. But the results revealed multiple 
limitations associated with the HD test, 
namely; it cannot be applied to coloured test 
substances with a strong absorption, it cannot 
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evaluate water-insoluble test substances, it 
cannot be applied to strong acids that exceed 
the buffering capacity of a phosphate buffer 
solution, and it cannot determine the potential 
for eye irritation caused by factors other than 
protein denaturation. Because of these 
limitations, the HD test alone is inappropriate 
for predicting eye irritation potential[375].  
Wang et al.[365], evaluated a novel micro-
patterned hepatocyte co-culture system for its 
ability to generate human in vivo metabolites. 
The co-culture system produced 82% of the 
excretory metabolites, exceeding the 
performance of hepatocyte suspension 
incubations and other in vitro systems. 
Unfortunately, in vitro systems possess some 
shortcomings when used to predict the total in 
vivo metabolism profiles in humans. Some 
systems are limited by the number/variety of 
drug-metabolising enzymes present, whilst 
others cannot perform the multiple sequential 
reactions required before the drug-related 
material is excreted. 
A more recent study by Chan et al.[368], 
looked at overcoming the short incubation 
times of primary hepatocytes in suspension 
used to predict in vivo clearance, as 4-6 hours  
is not long enough to accurately evaluate the 
metabolic stability of slowly metabolised 
compounds. Using a micro-patterned 
hepatocyte-fibroblast co-culture system 
(HepatoPac®), continuous incubations were 
performed for up to 7 days. Hepatic clearance 
was accurately predicted for 13 of 17 
compounds (76%; predicted clearance within 
3-fold of observed human in vivo clearance 
values).  
Testing with incubated hen's eggs is 
arguably a grey area between in vivo and in 
vitro systems, but is regarded as a preferable 
alternative to the Draize irritation test[376]. The 
Hen's Egg (or Hühner-Embryonen) Test-
Chorioallantoic Membrane (HET-CAM) is a 
rapid, sensitive, and inexpensive toxicity test. 
HET-CAM has a number of advantages over 
other alternative tests, particularly cytotoxicity 
tests, because the technique is applicable to all 
types of chemicals, regardless of their physical 
properties or solubility[377]. A study by 
Debbasch et al.[378] reported that the results of 
HET-CAM testing with strong irritants 
correlated well with Draize testing, but 
appeared less suited to identify mild irritants.  
The Syrian hamster embryo (SHE) cell 
transformation assay has been described as the 
most predictive short-term assay for rodent 
carcinogens, as it detects morphological cell 
transformation, the earliest identifiable stage in 
carcinogenesis[379]. Pienta et al.[380] 
demonstrated a 91% correlation between the 
morphological transformations of SHE cells 
and the reported carcinogenic activity of a 
multitude of carcinogenic and non-
carcinogenic chemicals. Although the SHE 
assay is still undergoing improvement, most of 
the difficulties encountered in earlier versions 
have been overcome by culturing SHE cells at 
pH 6.7[379, 381]. An overview of the in vitro 
alternative methods to evaluate irritation is 
given in Table 13. 
 
 Alternative organisms 
Various ethical arguments have resulted in a 
number of restrictions on the use of higher 
vertebrates, such as rats and monkeys, in 
animal testing. To overcome these restrictions 
and ethical arguments, the use of alternative 
organisms, such as lower vertebrates and 
invertebrates, has been suggested. 
Lower vertebrates, including the zebrafish 
(Danio rerio), are appealing alternatives to 
animal testing because of their genetic 
relatedness to higher vertebrates (including 
mammals), as well as the decrease in ethical 
issues, working space, cost of laboratory 
solutions, test chemicals, and manpower 
involved compared to animal testing[361, 382]. 
During early development, the body of the 
zebrafish is almost transparent, which helps 
easy visual access to the internal anatomy. This 
allows direct observation of developmental 
stages, the identification of phenotypic traits 
during mutagenesis, easy screening, 
assessment of endpoint of toxicity testing, and 
direct observation of gene expression through 
light microscopy[361]. 
As zebrafish embryos can survive for 
several days in a single well of a 384-well plate 
through the absorption of yolk, and can be 
visually assessed for malformation[383], it is 
possible to rapidly treat and screen large 
libraries of molecules for toxicity or 
therapeutic value. Using fluorescent 
transgenics, Peterson et al.[384], screened 1100 
small molecules and identified several that 
altered organ development. Likewise, Milan et 
al.[385], assessed 100 molecules that cause 
cardiac QT prolongation in humans, but 
manifested as bradycardia and AV block in 
zebrafish. 
Currently, acute toxicity studies using 
zebrafish are very limited. Examples of toxic 
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substances investigated include lead and 
uranium[386], malathion[387], metronidazole[388], 
anilines[389], and colchicine[390]. The main 
reason few studies have utilised juvenile and 
adult zebrafish is because the value of 
zebrafish lies in its genetics and developmental 
biology[382]. 
Invertebrates, including the common fruit 
fly (Drosophila melanogaster) have been 
extensively used as alternatives for animal 
testing to investigate a variety of diseases[361] 
and biomedical applications[391]. The results of 
tests on the common fruit fly is widely 
applicable to humans because of similarities in 
genetics[392, 393], anatomy[394], and CNS 
responses to drugs[394-396]. Although 
invertebrates have an undeveloped organ 
system and are not recognised to have an 
adaptive immune systems, which poses some 
limitations for their use in human 
diseases[361],  some genes in organisms such as 
C. intestinalis are related to those in 
vertebrates and give rise to adaptive 
immunity[397]. 
The fruit fly is considered a multiple 
model organism, used to study a number of 
different concepts[395]. For example, the 
embryo is used to study neuronal development, 
axon path finding, and organogenesis, whereas 
the larva is used to study physiological and 
developmental processes and behaviours[361]. 
Fruit flies are also used to express the 
protein products found in human diseases and 
to compare the resulting pathologic conditions, 
serving as important tools to investigate 
neurodegenerative diseases like Alzheimer’s, 
Parkinson’s disease, and Huntington’s 
disease[398-400]. 
A number of Drosophila phenotypes have 
been created as models for human disease[401]. 
Insulin signalling is very similar in flies and 
humans, making them ideal models to study 
the ways in which insulin regulates 
metabolism. However, Drosophila is not 
suitable to study all aspects of human 
metabolic control, as for example, the leptin 
signalling pathway is not present in the fly[402]. 
Drug delivery is a major challenge when 
using Drosophila, because of the extreme 
difficulty in standardising the amount of drug 
consumed in a fly’s diet[403]. Alternative 
administration options, such as microinjection 
into the abdomen, have been suggested[404]. In 
spite of this challenge, multiple studies have 
used Drosophila for toxicity testing[403, 405-407]. 
Researchers have observed negative 
reproductive effects in Drosophila adults and 
cell lines after exposure to variety of different 
insecticides[406, 407]. Similarly, Avanesian and 
colleagues[403] studied methotrexate toxicity in 
flies and found ovarian impairment 
comparable to that observed in mammalian 
models. 
Caenorhabditis elegans is a eukaryotic 
nematode, a transparent multicellular 
organism that has been used to study various 
diseases, such as Huntington’s disease, 
Parkinson’s disease, Alzheimer’s disease, 
various immune disorder, cancer, and 
diabetes[408-412]. It has also been used in both 
LD50 and behavioural pattern studies[413], 
showing results comparable to those of mouse 
systems[414]. 
The extrapolation of responses to 
chemicals from invertebrates to vertebrates 
presents a number of different problems. For 
example, asexual or parthenogenetic 
invertebrates are not suitable for the evaluation 
of effects on gametogenesis[391]. Additionally, 
some routes of entry are typical of vertebrates 
(e.g., lung and skin), but their importance in 
the penetration of chemicals cannot be 
assessed using invertebrates. For example, the 
cuticle of arthropods and the skin of 
vertebrates are very different in structure and 
relative permeability to substances[415-418]. 
 
 Microorganisms 
Brewer’s yeast (Saccharomyces cerevisiae) is 
one of the main microorganism used in 
experiments because of its rapid growth, ease 
of replication and mutant isolation, dispersed 
cells, well defined genetic system, highly 
versatile DNA transformation system, and the 
fact that its membrane-bound and secretory 
organelles mimic the functions of mammalian 
cells[419]. S. cerevisiae is used to comprehend 
apoptosis and cell death regulators for cancer 
research[420], as well as the cellular biology 
involved in neurodegenerative diseases[421, 422]. 
The most commonly used test for 
mutagenicity is the Ames test for “reverse 
mutation” in Salmonella typhimurium[423]. 
Mutagenicity is detected by exposing an 
already mutated strain to potential mutagens. If 
the mutation is reversed, the bacteria regain 
their ability to produce the amino acid 
histidine, allowing them to multiply in a 
histidine-deficient culture medium. The Ames 
S. typhimurium reverse mutation and 
chromosomal aberration genotoxicity assays 
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have been accepted by regulatory agencies for 
many years[424]. 
Tennant et al.[425] reported successfully 
predicting the outcomes of 86% of 44 
chemicals undergoing carcinogenicity testing, 
by using the Salmonella mutagenicity and sub-
acute (90-day) rodent toxicity tests, combined 
with chemical structural information. 
 
Justification for toxicology testing 
Main aim 
The primary aim of toxicity testing is to protect 
humans against the potential adverse effects of 
exposure to a wide variety of chemicals and 
substances, such as pharmaceuticals, cosmetics, 
household products, industrial chemicals, and 
agrochemicals[426].  The safety studies performed 
are used to identify the various toxicological 
endpoints; everything from skin irritation and 
corrosion, to acute systemic toxicity and 
carcinogenicity[347]. 
 
Toxicity studies in people 
The methods available to investigate the toxicity of 
chemicals in humans is limited for obvious 
reasons. Therefore, the information on the effects 
of chemicals in humans normally comes from 
either accidental exposure or the suicidal uptake of 
high doses[347]. Studies performed on the ADME of 
chemicals in humans can be used to characterise 
their toxicity, and are recognised as important 
contributions for future risk assessment[505-513].  
 
Why toxicity testing is required for drug 
development 
Toxicity testing is very important in the arena of 
drug development. Currently it costs 
approximately £2-3 billion and 12-15 years to 
launch a single drug into the market[514, 515].  Lead 
compounds usually go through ADMET 
(absorption, distribution, metabolism, excretion, 
and toxicity) analysis in vitro and in vivo before 
being put forward for clinical trials in humans. 
However, of the compounds that pass through pre-
clinical screening, almost 90% of them eventually 
fail during clinical trials, with one-third of failures 
ascribed to toxicity[516]. Additionally, about 90% of 
drug withdrawals are because of toxicity concerns, 
with drug-induced liver injury a chief source[517, 
518]. 
 
CONCLUSION 
 
Whilst progress has been made to develop a 
number of alternative techniques to in vivo testing, 
further progress is required to reduce the 
dependency of toxicity testing on live animals. 
Unfortunately, at the moment, in vitro methods 
cannot currently predict complex toxicological 
endpoints; however alternative testing methods 
could potentially reduce the number of animals 
used. 
The information presented in this review 
clearly demonstrates the versatility of 
biopolymers. It is still too early to speculate about 
the in vivo applicability of biopolymer-based 
scaffolds, due to the many unknowns regarding the 
biocompatibility of these scaffolds in vivo, as the 
immunological response and long-term stability of 
implanted biomaterials is still being studied.  
Multiple approaches to produce a 3D matrix 
that supports mammalian cell cultures are 
available, however a large number of these 
products are proprietary, costly, or require 
chemical synthesis. Furthermore, due to the 
interdisciplinary nature of tissue engineering, close 
collaboration between various research disciplines 
will be essential to develop the ideal biopolymer-
based organ structures. 
Successful production of biocompatible, 
biopolymer-based 3D organ structures that can be 
used for drug toxicity testing should eventually 
usher in the end of testing on animals. However, 
this will be dependent on artificial organ structures 
no-longer being cost prohibitive to produce, as 
well as the results produced using them being 
recognised by the relevant regulatory authorities. 
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Table 1. Materials used for Regenerative Medical Applications (adapted from Park and Bronzino, 2002[15]) 
Materials Examples Advantages Disadvantages Applications 
Biologically-derived 
materials, proteins and 
polysaccharides 
Agar, agarose, cellulose, 
chitosan, collagen, fibrin, 
hyaluronic acid, silk 
 Biologically active and 
compatible  
 Weak 
 Limited sources 
 Ethics 
 Immunoresponsive 
Soft and hard tissue repair, replacement, 
topical wound dressing, drug delivery, cell 
scaffold/matrix for culture applications 
Ceramics 
Aluminium oxide, carbon 
derivatives, calcium 
phosphates, hydroxyapatite 
 Very biocompatible 
 Inert 
 Strong in compression 
 Brittle and not resilient 
 Difficult to manufacture and 
manipulate  
Material coating, joint implants, scaffold 
material for cells 
Composites Carbon-carbon, wire or fibre reinforced cement 
 Strong 
 Customisable 
 Deforms with time 
 Degradable 
 Difficult to manufacture and 
manipulate 
Joint implants, material coating 
Metals Gold, silver, platinum, stainless steel, alloys 
 Strong 
 Tough 
 Ductile 
 Inert 
 Dense 
 Difficult to manufacture and 
manipulate 
 Costs 
 May suffer from corrosion 
Joint replacements, screw, wires, plates, 
material coating 
Synthetic polymers 
Nylon, silicone, polyester, 
polytetrafluoroethylene, 
rubber 
 Easy to fabricate 
 Tough 
 Ease of manipulation 
 Weak 
 Brittle 
 Deforms with time 
 Degradable 
Sutures, soft tissue replacement, cell culture 
matrix, drug delivery, scaffold support, 
wound dressing 
 
 
Table 3: Overview of Different 3D Culture Models used for Toxicity Studies (adapted from Fitzgerald et al., 2015[38]) 
Sample model system Cell lines 3D constructs or techniques exploited Key findings 
Cancer (breast) 
MDA-MB-231, MCF-
7, MDR-MCF-7, 
BT474, SKBR3, HS 
578T 
Non-mulberry silk fibroin protein 
scaffolds, multicellular spheroids, 
decellularised tissue 
Higher drug concentrations required to achieve comparable reduction in cell 
viability and invasive potential compared to 2D cultures, 3D culture induces 
increase doxorubicin resistance in parental cells but not in MDR cells, 3D cells 
displayed reduced sensitivity relative to 2D cells, BT474 and SKBR3 cells more 
sensitive to treatment than 2D cultured cells 
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Cancer (lung) 
Primary cells, SPCA-1 
co-cultured with HFL1, 
H460M, NCI-H460, 
SA87 
Microfluidic device, hyaluronan 
hydrogel 
Discrepancies noted between 3D and 2D culture systems in addition to primary 
versus established cell lines, IC50 values for certain drugs were higher for cells 
in 3D culture compared to 2D culture, paclitaxel was significantly less toxic to 
tumour cells grown as multicellular aggregates 
Cancer (prostate) PC3, LNCaP, C4-2B Collagen-based scaffold, hyaluronic acid-based hydrogels 
Cell lines in 3D culture demonstrated higher drug resistance, higher and faster 
apoptotic resistance observed in cells cultured in 3D 
Cancer (others) 
Panc-1 (pancreatic), 
PA-1 (ovarian), COLO 
205 (colorectal), U87 
(glioblastoma), BGC-
823 (gastric) 
Fibroblast-derived 3D matrix, pre-
conditioned ECM, multicellular 
spheroids, poly(lactide-co-glycolide) 
and derivatives, poly(3-
hydroxybutyrate-co-3-hydroxyvalerate) 
and collagen peptide based nanofibers, 
MatrigelTM, collagen-based gels 
Increased drug resistance noted in 3D cultures compared to 2D system, higher 
drug exposure and duration required to exert comparable effect on 3D culture 
compared to cells as monolayers 
Heart 
Isolated rat myocytes, 
neonatal mouse, Wistar 
rat myocytes 
Co-culture, collagen gel, MatrigelTM 
3D culture demonstrated acceleration of contraction kinetics, specific for testing 
of atorvastatin on contraction after establishing in 2D culture that it decreases 
isoprenylation of Gɣ 
Kidney  
NK-i2, HEK293, 
murine proximal tubule 
epithelial, Vero, 
Madin-Carby canine 
kidney, LLC-PK1, 
CaKi-1, rat MSC, 
LZ100, podocytes, 
primary human 
Collagen, MatrigelTM, hyaluronic acid 
hydrogel, fibrin microbeads, 
microfluidic chip, culture chamber, 3D 
organoid culture  
3D models have different time of toxicity induction and lower LD50/sensitivity 
value, comparable data observed in 3D compared to animal kidney injury 
models, microbead system demonstrated multilayer growth and relative 
resistance to cell killing and lysis by oncolytic viruses, metabolism closely 
represented using microfluidic device, comparable biomarker expression of 
cells to animal and clinical studies when grown in 3D culture 
Liver 
Human hepatocytes, 
HepaRG, primary rat 
cells, HepaG2/G3a, 
Hurel microfluidics, organoids, 
biochips, co-culture  
Predictive hepatic clearance correlation superior in 3D culture, higher 
sensitivity for toxicity observed in 3D system 
 
 
 
Table 13: In vitro Alternative Methods to Evaluate Irritation[426] 
In vitro Alternatives Model Systems Endpoints References 
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In vitro eye irritation tests 
Red blood cell test RBCs of bovine, sheep, rabbit, and calf Haemolysis and haemoglobin denaturation [427-432] 
Haemoglobin denaturation Bovine haemoglobin Spectrophotometric changes in haemoglobin [374, 375, 433-435] 
HET-CAM Chorioallantoic membrane of White Leghorn eggs Haemorrhage, vasoconstriction, coagulation, trypan blue adsorption [376-378, 436-447] 
Isolated cornea Isolated bovine cornea Corneal opacity and permeability [448, 449] 
Isolated eyes Isolated eyes of rabbits, cows, pigs, chickens Corneal swelling, corneal opacity, fluorescein retention [450, 451] 
Cell culture 
• Rabbit corneal epithelial cells 
• Human corneal endothelial cells 
• Bovine corneal stroma 
• Bovine epithelium 
• Madin-Darby canine kidney cells 
Fluorescein leakage, neutral red release [452-460] 
Commercial kits 
 EYTEX® Medium containing proteins, glycoproteins, and mucopolysaccharides Turbidity [461-463] 
 Reconstituted corneal 
epithelium 
3D model of human corneal epithelium, composed of 
normal human-derived epidermal keratinocytes Tissue viability (MTT assay) [464-466] 
In vitro skin irritation 
Cell culture 
• Human epidermal keratinocytes 
• Murine epidermal keratinocytes 
• Mouse immortalised fibroblasts (3T3) 
Cell Viability (NRU or MTT assay), cytotoxicity (LDH 
and NAG release), metabolism (glucose utilisation), 
inflammatory mediator release (PGE-2, IL-6, IL-1α) 
[467-478] 
Commercial kits 
 SkintexTM 
Modified keratin/collagen membrane, containing an 
indicator compound and a globulin/protein 
macromolecular reagent solution 
Turbidity [479, 480] 
 Human epidermal models Human skin cultures Cell death, release of IL-1α, cell viability [479, 481] 
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In vitro skin corrosivity 
Commercial kits 
 Corrositex® Biobarrier comprising a hydrated collagen matrix Colour change [482, 483] 
 EpiDerm® Normal human epidermal keratinocytes (NHEK) Cell viability (MTT assay), membrane damage (extracellular release of IL-1α, LDH, and GOT) [481, 484-487] 
 EPISKINTM Reconstructed organotypic culture composed of human adult keratinocytes 
Cell viability (MTT assay), membrane damage 
(extracellular release of adenylate kinase, IL-1α, IL-8, 
LDH, and GOT) 
[481, 485, 486, 488-
492] 
Transcutaneous electrical 
resistance Isolated rat skin Reduction in TER, degree of colour staining [493-496] 
In vitro phototoxicity 
Red blood cell phototoxicity Mouse immortalised fibroblasts (3T3) Photohaemolysis [497] 
3T3 NRU phototoxicity • Mouse immortalised fibroblasts (3T3) • Human immortalised keratinocytes (HaCaT) Cell viability (as determined by NRU) [498-500] 
Keratinocyte cell culture 
• Human epithelial carcinoma cells (A431) 
• Mouse immortalised fibroblasts (3T3) 
• Primary human keratinocytes, isolated from human 
foreskin 
Cell viability (NRU or MTT assay) [501-503] 
Skin equivalent model 
Normal human keratinocytes, seeded onto a collagen-
glycosaminoglycans-chitosan porous matrix populated by 
normal human fibroblasts. 
Cell viability (determined by MTT assay, or extracellular 
release of IL-1α) [504] 
Abbreviations: 
GOT, glutamicoxaloacetic transaminase; IL, Interleukin; LDH, lactate dehydrogenase; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; 
NAG, N-Acetylglucosamine; NRU, neutral red uptake; PG, prostaglandin; RBC, red blood cell; TER, transcutaneous electrical resistance. 
 
